Yixin AI Organ Chip Company received tens of millions of angel round financing, and Light Cone Frontier Technology Fund participated in the investment

Ji Shisan, founding partner of the Future Light Cone Frontier Technology Fund and CEO of Guoke.com, said: “The acceleration of the pharmaceutical industry will face many obstacles, and using organ chips to partially replace animal experiments in preclinical work, I think, is an embrace of the upcoming AI. A key step in the pharmaceutical era. Research in this area is a relatively new field in the world. Professor Liu Jie’s team has a very rare background in composite medical engineering and pharmaceuticals, as well as firm entrepreneurial determination and mature industrial thinking. I hope they can Contribute to the cause of China’s innovative drugs.”

Recently, Guangzhou Yixin Life Sciences Co., Ltd., a cutting-edge company in the field of AI organ chips, announced that it has successfully completed tens of millions of angel rounds of financing. Core Air Capital led the investment and Future Light Cone Frontier Technology Fund followed.

Yixin Company focuses on the research and development of AI organ chip microphysiological systems. Relying on biomaterials, stem cells and microfluidic chip technology, it has successfully established the world's first full-process market-oriented, standardized and intelligent organ chip R&D platform. The platform is actively promoting the application of organ chips in the fields of precision medicine, innovative drug development, disease modeling and regenerative medicine

Organ-on-a-chip is one of the "Top Ten Emerging Technologies" listed by the World Economic Forum in Davos. It uses engineering technologies such as microfluidics and 3D bioprinting to build miniature dynamic organ models in vitro that are close to the basic physiological functions of the human body by using stem cells or patient-derived tissue cells as seeds. This technology has improved the means and methods of in vitro exploration of life phenomena and medical problems, and has had a revolutionary impact on basic research and applications in the field of life sciences

In the past, new drug research mainly relied on 2D cell models and animal models. However, 2D cell models are too simple, and animal experiments have problems such as long cycle times, poor reproducibility, high experimental costs, and the inability to accurately predict human responses, which seriously hinder the drug development process. The emergence of organ-on-a-chip allows researchers to reconstruct the microenvironment of human organs in a controllable and scalable manner and can simulate different types of disease models. This technology breaks through the limitations of 2D cell models and animal models, and is expected to accelerate the development of new drugs for thousands of diseases. In August 2022, the U.S. Food and Drug Administration approved a new drug NCT04658472 to enter clinical trials for the first time. The drug did not use efficacy data provided by traditional animal experiments and was entirely based on preclinical efficacy data obtained from organ-on-chip research. This milestone event marks a major breakthrough in the application of organ chips and defines 2022 as the "first year of organoid standardization"

After more than 10 years of rapid development, the organ chip industry is now ushering in a golden opportunity period. According to research firm Mordor Intelligence, the global organ chip market will grow rapidly at a compound annual growth rate of 30% from 2022 to 2027. Data from the U.S. FDA also shows that the number of applications for new drugs and biological products powered by AI has increased dramatically in recent years, which means that the combination of AI pharmaceuticals and organ-on-chips will have a broader market.

Yixin founder Liu Jie is a Ph.D. from Yale University in the United States and a distinguished professor of Yixian Scholars at Sun Yat-sen University. He has long been engaged in research on tumor targeted therapy and organ-on-chip in vitro microphysiological systems, and has proposed and developed a world-leading new material, a nanocarrier for efficient gene delivery. He also pioneered the construction of China's first three-dimensional organoid culture system based on naturally derived polymer materials, and published nearly a hundred high-level papers in top domestic and foreign journals such as "Nature Materials". As early as 2018, Professor Liu Jie led a team with biomedical engineering background and multidisciplinary capabilities to enter the field of organ chips, and accumulated rich technical capabilities, pharmaceutical experience, and strong technical capabilities in organoids and microfluidic chips. engineering implementation capabilities. They can provide personalized customized services according to the diverse needs of the industry

Yixin constructs engineered in vitro microphysiological systems by developing new bioactive materials and organ chips in vitro, and constructs organ chip models with different physiological structures in vitro such as barriers, bionic tumors, vascularization, and rare diseases. to simulate the microphysiological environment in the body. Relevant technical capabilities and products have great potential in high-throughput applications in fields such as personalized precision drug screening, rare disease modeling, organ regeneration, cosmetics research and development, and innovative drug development.

Yixin also innovatively integrates organ chips with AI technology to bring greater driving force for change in the field of innovative drug research and development. Yixin is conducting joint research and development with AI drug research and development companies to integrate organ chips and AI pharmaceutical technology to develop an end-to-end AI innovative drug research and development system. Previously, while AI increased the speed of drug development, it also derived a large number of products during the development process. The use of high-throughput wet experiment technology to verify dry experiment results was an indispensable part. Organ-on-a-chip has the unique ability of high-throughput organoid culture and drug screening, and can work closely with AI to form a dry-wet closed loop to achieve rapid design, verification, and iteration, further improving research and development efficiency and success rate, and accelerating the introduction of more innovative drugs to the market. .

Based on artificial intelligence and automation technology, Yixin is committed to promoting the standardization and automation of organ chips to replace the traditional manual laboratory operation mode. In this way, users can construct the required simulated organ micro-tissues in a simpler and more reproducible way, thereby greatly reducing application costs

Yixin founder Liu Jie said: "Yixin will be based on its unique advantages in cross-research fields such as biomaterials, microfluidics and targeted drug development, from organ chip underlying material technology, in vitro disease models, drug evaluation and development, to create the world's first full-process market-oriented, standardized and intelligent organ chip research and development platform, to achieve industrial applications in the fields of precision drug screening, rare disease modeling, innovative drug development and organ regeneration, and to provide new drugs Development, precision treatment, and AI pharmaceuticals provide a transformative R&D paradigm.”

Xu Jing, founding partner of Core Air Capital, said: "Professor Liu Jie is a very rare outstanding scholar in the industry who has rich experience in targeted drug research and development and organ chip engineering. We look forward to the future integration of organ chip technology and artificial intelligence by Core Air Capital." The combination of intelligence and automation creates a more comprehensive understanding of drug molecules, creates a new generation of high-throughput drug discovery platform, and accelerates innovation in new drug development, precision treatment, AI pharmaceuticals and other fields.”

The above is the detailed content of Yixin AI Organ Chip Company received tens of millions of angel round financing, and Light Cone Frontier Technology Fund participated in the investment. For more information, please follow other related articles on the PHP Chinese website!